Chapter 3 . 2 Comparison of 2 D ( RANO ) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab – a report from the BELOB trial

@inproceedings{Vernhout2019Chapter3,
  title={Chapter 3 . 2 Comparison of 2 D ( RANO ) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab – a report from the BELOB trial},
  author={Vernhout and Walter Taal and Maaike J. Vos and Jan Cees de Groot and Laurens V. Beerepoot and Jeffrey Buter and Zwenneke H. Flach and Monique C J Hanse and Bas Jasperse and Marion Smits},
  year={2019}
}
Background. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on post-contrast T1w, and a more infiltrative non-enhancing growth pattern on T2w/FLAIR-images. We investigated whether the RANO criteria remain the method of choice for assessing bevacizumab-treated recurrent glioblastoma when compared to various volumetric methods. Methods… CONTINUE READING

Figures and Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES